The Value of Hsa_circ_0058514 in Plasma Extracellular Vesicles for Breast Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Nov 17

PMID 36387225

Authors

Jiani Liu

Xinyu Peng

Yang Yang

Yao Zhang

Meng Han

Xiaohui Shi

Jie Zheng

Tong Li

Jinxia Chen

Weihua Lv

Yunjiang Liu

Yixin Qi

Lei Zhang

Qi Liu

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to investigate the diagnostic value of hsa_circ_0058514 in plasma extracellular vesicles (EVs) in BC patients and its predictive value for neoadjuvant chemotherapy. The expression of hsa_circ_0058514 in a large sample of BC plasma and healthy subjects' plasma was detected by qPCR, and the ROC curve was drawn to verify its diagnostic value as a plasma tumor marker. Furthermore, the association between the expression of hsa_circ_0058514 and clinicopathological characteristics before and after treatment was detected in the plasma of 40 pairs of BC patients undergoing neoadjuvant therapy. The expression level of hsa_circ_0058514 in the plasma of BC patients was significantly higher than that of healthy subjects. The ROC curve showed that plasma hsa_circ_0058514 ROC in differentiating non-metastatic BC and healthy people had better diagnostic efficiency than conventional tumor markers CA153, CA125, and CEA. In patients with neoadjuvant therapy, the decrease in plasma hsa_circ_0058514 value before and after treatment correlated with pathological MP grade ( = 0.444, = 0.004) and imaging tumor regression value ( = 0.43, = 0.005) positive correlation. The detection of hsa_circ_0058514 in both extracellular vesicles of BC cell culture medium and human plasma was demonstrated. Hsa_circ_0058514 is detected in the plasma from BC cells secreted in the form of vesicles. Hsa_circ_0058514 can be used as an early plasma biological indicator for the diagnosis of BC in clinical applications, with a higher risk of recurrence and metastasis, and as a predictor of the effect of neoadjuvant therapy to guide the clinical use of neoadjuvant therapy.

References

Li H, Xie Q, Nie Q, Ye X . Prostate specific antigen as a biomarker for breast cancer: a meta-analysis study. Eur Rev Med Pharmacol Sci. 2018; 22(13):4188-4195. DOI: 10.26355/eurrev_201807_15412. View

Naito Y, Yamamoto Y, Sakamoto N, Shimomura I, Kogure A, Kumazaki M . Cancer extracellular vesicles contribute to stromal heterogeneity by inducing chemokines in cancer-associated fibroblasts. Oncogene. 2019; 38(28):5566-5579. PMC: 6755971. DOI: 10.1038/s41388-019-0832-4. View

Verma M, Lam T, Hebert E, Divi R . Extracellular vesicles: potential applications in cancer diagnosis, prognosis, and epidemiology. BMC Clin Pathol. 2015; 15:6. PMC: 4399158. DOI: 10.1186/s12907-015-0005-5. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Nair A, Niu N, Tang X, Thompson K, Wang L, Kocher J . Circular RNAs and their associations with breast cancer subtypes. Oncotarget. 2016; 7(49):80967-80979. PMC: 5348369. DOI: 10.18632/oncotarget.13134. View

Rahbarghazi R, Jabbari N, Sani N, Asghari R, Salimi L, Kalashani S . Tumor-derived extracellular vesicles: reliable tools for Cancer diagnosis and clinical applications. Cell Commun Signal. 2019; 17(1):73. PMC: 6617682. DOI: 10.1186/s12964-019-0390-y. View

Tay T, Tan P . Liquid Biopsy in Breast Cancer: A Focused Review. Arch Pathol Lab Med. 2020; 145(6):678-686. DOI: 10.5858/arpa.2019-0559-RA. View

Raposo G, Stahl P . Extracellular vesicles: a new communication paradigm?. Nat Rev Mol Cell Biol. 2019; 20(9):509-510. DOI: 10.1038/s41580-019-0158-7. View

Zhao T, Wu L, Li X, Dai H, Zhang Z . Large intergenic non-coding RNA-ROR as a potential biomarker for the diagnosis and dynamic monitoring of breast cancer. Cancer Biomark. 2017; 20(2):165-173. DOI: 10.3233/CBM-170064. View

10.

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

11.

Yang R, Xing L, Zheng X, Sun Y, Wang X, Chen J . The circRNA circAGFG1 acts as a sponge of miR-195-5p to promote triple-negative breast cancer progression through regulating CCNE1 expression. Mol Cancer. 2019; 18(1):4. PMC: 6325825. DOI: 10.1186/s12943-018-0933-7. View

12.

Lyu L, Zhang S, Deng Y, Wang M, Deng X, Yang S . Regulatory mechanisms, functions, and clinical significance of CircRNAs in triple-negative breast cancer. J Hematol Oncol. 2021; 14(1):41. PMC: 7937293. DOI: 10.1186/s13045-021-01052-y. View

13.

Xu Z, Yan Y, Zeng S, Dai S, Chen X, Wei J . Circular RNAs: clinical relevance in cancer. Oncotarget. 2018; 9(1):1444-1460. PMC: 5787450. DOI: 10.18632/oncotarget.22846. View

14.

Xue Y, Ding M, Xue L, Luo J . CircAGFG1 sponges miR-203 to promote EMT and metastasis of non-small-cell lung cancer by upregulating ZNF281 expression. Thorac Cancer. 2019; 10(8):1692-1701. PMC: 6669801. DOI: 10.1111/1759-7714.13131. View

15.

Zhang D, Li C, Cheng N, Sun L, Zhou X, Pan G . CircAGFG1 acts as a sponge of miR-4306 to stimulate esophageal cancer progression by modulating MAPRE2 expression. Acta Histochem. 2021; 123(7):151776. DOI: 10.1016/j.acthis.2021.151776. View

16.

Pesapane F, Suter M, Rotili A, Penco S, Nigro O, Cremonesi M . Will traditional biopsy be substituted by radiomics and liquid biopsy for breast cancer diagnosis and characterisation?. Med Oncol. 2020; 37(4):29. DOI: 10.1007/s12032-020-01353-1. View

17.

Wu F, Zhou J . CircAGFG1 promotes cervical cancer progression via miR-370-3p/RAF1 signaling. BMC Cancer. 2019; 19(1):1067. PMC: 6842182. DOI: 10.1186/s12885-019-6269-x. View

18.

Lin L, Cai G, Zhai X, Yang X, Li M, Li K . Plasma-Derived Extracellular Vesicles Circular RNAs Serve as Biomarkers for Breast Cancer Diagnosis. Front Oncol. 2021; 11:752651. PMC: 8660094. DOI: 10.3389/fonc.2021.752651. View

19.

Patop I, Kadener S . circRNAs in Cancer. Curr Opin Genet Dev. 2017; 48:121-127. PMC: 5877416. DOI: 10.1016/j.gde.2017.11.007. View

20.

Sadeghalvad M, Mohammadi-Motlagh H, Rezaei N . Immune microenvironment in different molecular subtypes of ductal breast carcinoma. Breast Cancer Res Treat. 2020; 185(2):261-279. DOI: 10.1007/s10549-020-05954-2. View